Emerging metabolic targets in the therapy of hematological malignancies.
about
Inhibition of glucose metabolism prevents glycosylation of the glutamine transporter ASCT2 and promotes compensatory LAT1 upregulation in leukemia cells.Targeting of cell metabolism in human acute myeloid leukemia--more than targeting of isocitrate dehydrogenase mutations and PI3K/AKT/mTOR signaling?Reversion of apoptotic resistance of TP53-mutated Burkitt lymphoma B-cells to spindle poisons by exogenous activation of JNK and p38 MAP kinases.2-Deoxy-D-glucose Restore Glucocorticoid Sensitivity in Acute Lymphoblastic Leukemia via Modification of N-Linked Glycosylation in an Oxygen Tension-Independent Manner.Reversal of the glycolytic phenotype of primary effusion lymphoma cells by combined targeting of cellular metabolism and PI3K/Akt/ mTOR signaling.
P2860
Emerging metabolic targets in the therapy of hematological malignancies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Emerging metabolic targets in the therapy of hematological malignancies.
@en
Emerging metabolic targets in the therapy of hematological malignancies.
@nl
type
label
Emerging metabolic targets in the therapy of hematological malignancies.
@en
Emerging metabolic targets in the therapy of hematological malignancies.
@nl
prefLabel
Emerging metabolic targets in the therapy of hematological malignancies.
@en
Emerging metabolic targets in the therapy of hematological malignancies.
@nl
P2093
P2860
P921
P356
P1476
Emerging metabolic targets in the therapy of hematological malignancies.
@en
P2093
Alexandre Arcaro
Geetha Parakkal
Zaira Leni
P2860
P304
P356
10.1155/2013/946206
P407
P5008
P577
2013-08-18T00:00:00Z